ArticleCureus2025
Comparative Effectiveness of Dual Antiplatelet Therapy Versus Single Antiplatelet Therapy in Patients With Acute Stroke.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective observational cohort study aimed to evaluate the comparative effectiveness of dual antiplatelet therapy (DAPT) versus single antiplatelet therapy (SAPT) in patients presenting with acute stroke at a tertiary care center in Muzaffarabad. A total of 250 patients aged 40-89 years (mean age=63.89; n=136; 54.4% female) were included, categorized into DAPT (n=129) or SAPT (n=121) groups. Baseline characteristics were evenly distributed, including hypertension (n=127; 50.8%), diabetes (n=120; 48%), and hyperlipidemia (n=124; 49.6%). The main outcome was recurrence of ischemic stroke within 90 days, confirmed by clinical assessment and neuroimaging (computed tomography (CT) or magnetic resonance imaging (MRI)). Secondary outcomes included any bleeding event (defined as documented clinical bleeding with no methodological categorization into major bleeding, minor bleeding, bleeding at a particular site, or bleeding by time), and mortality from any cause. The following medical comorbidities were recorded in patients: stroke in 133 (53.2%), bleeding in 131 (52.4%), and mortality in 127 (50.8%). Independent samples t-tests and chi-squared tests showed no significant difference in recurrence, bleeding, or mortality between treatment arms (p>0.05). Logistic regression indicated that former smoking (OR=0.331; p=0.003), transient ischemic attack (TIA) history (OR=1.884; p=0.031), and aspirin use (OR=0.468; p=0.012) were significant predictors of stroke recurrence. DAPT was not an independent predictor (p=0.583). These findings suggest that while DAPT may offer theoretical benefits, it was not significantly superior to SAPT in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.